These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21524743)

  • 1. [Calcific uremic arteriolopathy. a case report and review of the literature].
    Vassallo M; Bello I; Hamana L; Ferrer A; Rojas F; Cantele H
    Rev Clin Esp; 2011; 211(7):e37-41. PubMed ID: 21524743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series.
    Basile C; Montanaro A; Masi M; Pati G; De Maio P; Gismondi A
    J Nephrol; 2002; 15(6):676-80. PubMed ID: 12495283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pivotal role of paricalcitol in the treatment of calcific uremic arteriolopathy in the presence of a parathyroid adenoma.
    Vargemezis V; Liakopoulos V; Kriki P; Panagoutsos S; Leontsini M; Passadakis P; Thodis E
    Am J Kidney Dis; 2010 Jan; 55(1):144-7. PubMed ID: 19481317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calciphic uremic arteriolopathy complicating chronic kidney disease.
    Rodríguez-Pérez S; Ramirez-Rivera J; Jaume-Anselmi F; Torres AB
    Bol Asoc Med P R; 2008; 100(3):47-50. PubMed ID: 19227717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical image. A rare but fatal complication of end stage renal disease: calcific uremic arteriolopathy.
    Aarti M; Shweta P; Ankur S; Swathi B; Jiang J; Ambika B
    N Z Med J; 2012 Mar; 125(1352):106-9. PubMed ID: 22472720
    [No Abstract]   [Full Text] [Related]  

  • 6. Recognizing calcific uremic arteriolopathy in autoimmune disease: an emerging mimicker of vasculitis.
    Lee JL; Naguwa SM; Cheema G; Gershwin ME
    Autoimmun Rev; 2008 Sep; 7(8):638-43. PubMed ID: 18774119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Questionable specificity of histologic findings in calcific uremic arteriolopathy.
    Ellis CL; O'Neill WC
    Kidney Int; 2018 Aug; 94(2):390-395. PubMed ID: 29885932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates.
    Hanafusa T; Yamaguchi Y; Tani M; Umegaki N; Nishimura Y; Katayama I
    J Am Acad Dermatol; 2007 Dec; 57(6):1021-5. PubMed ID: 18021849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calciphylaxis: a case report.
    Strippoli D; Simonetti V; Russo G; Motolese A
    Dermatol Ther; 2008; 21 Suppl 3():S26-8. PubMed ID: 19076628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calciphylaxis: an uncertain pathogenesis and controversial treatment].
    Marrón B; Coronel F; López-Bran E; Barrientos A
    Nefrologia; 2001; 21(6):596-600. PubMed ID: 11881431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcoidosis-associated hypercalcemia potentiating calcific uremic arteriolopathy in a patient with a left ventricular assist device.
    Hankinson SJ; Patel SA; Kesari V; Ramani GV; Ton VK
    J Card Surg; 2019 Oct; 34(10):1137-1139. PubMed ID: 31389631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcific uremic arteriolopathy: advances in pathogenesis and treatment.
    Rogers NM; Teubner DJ; Coates PT
    Semin Dial; 2007; 20(2):150-7. PubMed ID: 17374090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous necrosis from calcific uremic arteriolopathy.
    Coates T; Kirkland GS; Dymock RB; Murphy BF; Brealey JK; Mathew TH; Disney AP
    Am J Kidney Dis; 1998 Sep; 32(3):384-91. PubMed ID: 9740153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous necrosis by calcific uremic arteriolopathy.
    Galimberti RL; Farias Edos R; Parra IH; Algranati L; Kowalczuk A; Imperiali N; Greloni GC; Galimberti G
    Int J Dermatol; 2005 Feb; 44(2):101-6. PubMed ID: 15689205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcific uremic arteriolopathy: overview for the nurse.
    Anderson KG
    AACN Adv Crit Care; 2013; 24(3):285-300. PubMed ID: 23880751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulminant metastatic calcinosis with cutaneous necrosis in a child with end-stage renal disease and tertiary hyperparathyroidism.
    Zouboulis CC; Blume-Peytavi U; Lennert T; Stavropoulos PG; Schwarz A; Runkel N; Trautmann C; Orfanos CE
    Br J Dermatol; 1996 Oct; 135(4):617-22. PubMed ID: 8915159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcific uremic arteriolopathy: contemporary pharmacotherapy.
    Mason D; Best SD
    Adv Chronic Kidney Dis; 2010 Sep; 17(5):428-38. PubMed ID: 20727513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcific uremic arteriolopathy in a patient on hemodialysis.
    Tarrass F; Benjelloun M
    Saudi J Kidney Dis Transpl; 2008 Jul; 19(4):643-5. PubMed ID: 18580028
    [No Abstract]   [Full Text] [Related]  

  • 20. Calcific uremic arteriolopathy should be treated conservatively.
    Courtney MJ; Pannu N
    Semin Dial; 2010; 23(1):34-7. PubMed ID: 20331816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.